Skip to NavigationSkip to content

AstraZeneca's Farxiga fails to get FDA approval for patients with Type 1 diabetes

Published on 15/07/19 at 10:33am

The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in adults with Type 1 diabetes who haven’t been able to control their condition with insulin alone.

Farxiga is currently approved in the United States for adults with Type 2 diabetes, the more common form of the condition.

The US regulator has however declined to approve the drug for use in patients with Type 1 diabetes. AstraZeneca did not say what specific concerns had been raised by the FDA.

The decision comes after the EMA approved Fraxiga, under the name Forxiga, for use in in patients with Type 1 diabetes earlier this year.

Type 1 diabetes (in which the pancreas produces little or no insulin) affects around 5% of all patients with diabetes.

Farxiga is one of AstraZeneca’s biggest selling drugs – the diabetes med having generated $1.39 billion in sales in 2018.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches